

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	
Maria PRAT QUINONES	)	Group Art Unit: Unknown
	)	
Application No.: 10/518,714	)	Examiner: Unknown
	)	
Filed: December 22, 2004	)	
	)	
For: NEW QUINUCLIDINE AMIDE	)	Confirmation No.: Unknown
DERIVATIVES, <u>being a U.S.</u>	)	
<u>National Phase Application</u>	)	
<u>based on PCT/EP2003/006708,</u>	)	
<u>filed June 25, 2003</u>	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Box: PCT**

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.**  
**§ 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents cited in the International Search Report as set forth on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.

The U.S. Patent listed on the PTO/SB/08 is not enclosed.

The following applies to the attached non-English document:

**FR 2 012 964**—Applicant is listing U.S. Patent No. 3,714,357 in the attached form PTO /SB/08, which is believed to be related to FR 2 012 964.

The following are listed on the accompanying PTO/SB/08 and are in a non-English language:

1. WO93/16048;
2. JP9-328469; and
3. WO02/00652.

An English-language abstract of the documents are enclosed.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute “prior art.” If the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute “prior art” under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: July 29, 2005

By: 

Anthony C. Tridico  
Reg. No. 45,958

<b>IDS Form PTO/SB/08: Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number		10/518,714
				Filing Date		December 22, 2004
				First Named Inventor		Maria PRAT QUINONES
				Art Unit		
				Examiner Name		
Sheet	1	of	1	Attorney Docket Number		09605.0008

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-3,714,357	01/30/1973	Gueremy et al	

**Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004**

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		WO93/16048	8/19/1993	Fujisawa Pharmaceutical Co., Ltd.		Abstract
		EP 0 747 355 A1	12/11/1996	Yamanouchi Pharmaceutical Co., Ltd.		N/A
		EP 0 424 021 A1	04/24/1991	Pfizer Inc.		N/A
		EP 0 801 067 A1	10/15/1997	Yamanouchi Pharmaceutical Co. Ltd.		N/A
		EP 0 863 141 A1	09/09/1998	Banyu Pharmaceutical Co., Ltd.		N/A
		FR 2,012,964	03/27/1970	SOGERAS		No
		JP 9-328469	12/22/1997	Fujisawa Pharmaceutical Co., Ltd.		Abstract
		WO02/00652	01/03/2002	Laboratorios S.A.L.V.A.T., S.A.		Abstract

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		Abstract from Patent Abstracts of Japan for 09-328469, published December 22, 1997.	
		L. Noronha-Blob et al., "Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate", <i>European Journal of Pharmacology</i> , Vol. 221, pp. 97-103, 1992.	
		S.H. Gao et al., "Stereochemistry of the Heterocyclic Alcohols Containing Piperidine Unit", <i>Chemical Journal of Chinese Universities</i> , Vol. 20, No. 2, pp. 232-236, 1999.	Abstract
		J. Lars et al., "Some quinuclidine derivatives with potential antimalarial activity", <i>Acta Pharm. Suecica</i> , Vol. 5, pp. 71-76, 1968.	
		N.N. Godovikov, et al., "Synthesis and muscarinolytic activity of quinuclidinyl benzilate alkyl iodides", <i>Khim. Farm. Zh.</i> , Vol. 19, No. 9, pp 1060-1061, 1985.	Abstract

Examiner Signature	/Niloofer Rahmani/	Date Considered	02/20/2008
-----------------------	--------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/